Latest "Standard & Poor’s" News Stories - Page: 5

11:30 EST 22nd January 2019 | BioPortfolio

Here are the most relevant search results for "Standard & Poor’s" found in our extensive news archives from over 250 global news sources.

More Information about Standard & Poor’s on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Standard & Poor’s for you to read. Along with our medical data and news we also list Standard & Poor’s Clinical Trials, which are updated daily. BioPortfolio also has a large database of Standard & Poor’s Companies for you to search.

Showing "Standard Poor" News Articles 101–125 of 3,300+

Tuesday 15th January 2019

Specsavers Uses Topcon OCT In Its Stores

Topcon Healthcare Solutions, Inc., a wholly-owned subsidiary of Topcon America Corporation (“Topcon”) based in Oakland, NJ, has announced that eye health provider Specsavers had recently completed equipping its stores with Topcon's Optical Coherence Tomography (OCT) instruments. On September 21, 2018, Specsavers had reported that Specsavers Blacktown (...

Sphere Fluidics collaborates with Peak Analysis and Automation to increase throughput in antibody discovery and cell line development

  PAA’s S-LAB micro-plate handling capability will be integrated with Sphere Fluidics’ Cyto-Mine Single Cell Analysis System  Cambridge and Farnborough, UK, 15 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the d...

RSNA: Personalized Treatment Benefits Kidney Cancer Patients

Personalized treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published Tuesday, January 15, in the journal Radiology. OAK BROOK, Ill. (PRWEB) January 15, 2019 Personalized treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsenin...

Nivolumab/Ipilimumab Combo Approved in Europe for Frontline RCC

The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Philadelphia Eye Associates Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

Mark Blecher, M.D. at Philadelphia Eye Associates in Philadelphia, Pa., is participating in the AcuFocus clinical study for the IC-8 intraocular lens (IOL) designed for patients with cataracts. “Participating i

FDA Additionally Clears RAPID™ Imaging Platform for Use in Selecting Acute Stroke Patients for Clot Removal

Approval Puts RAPID in a Class of Its Own for Diagnosing and Treating Stroke iSchemaView, the worldwide leader in advanced imaging for stroke, today announced that the FDA has cleared the RAPID neuroimaging platform for use in selecting stroke patients who are likely to benefit from endovascular thrombectomy (clot removal). Specifically, this additiona...

Stool Processing Method Might Be Important for Efficacy in Fecal Transplantation Protocols

Odds of short-term remission in ulcerative colitis were higher using anaerobically prepared pooled donor stool versus standard autologous stool.

CAQH Develops the First Provider Data Management Solution for Delegated Groups with Support from Accenture

Cloud-based platform leverages micro-services and a highly flexible database to enable improved user experience Accenture (NYSE:ACN) has helped CAQH, a non-profit healthcare alliance, launch a new technol

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

FDA’s record-breaking year for approvals affirms high value provided by model-informed drug development Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2018 ...

Stillwater Ingredients Fuels VYBES, Largest Hemp CBD Beverage by Market Share in the U.S.

Closing Out First Year in Distribution, VYBES Expands to 1,400 stores in 17 states, and More Than 1.1 Million Bottles Produced As it rounds out its first year of sales, VYBES, a line of organic, ready-to-drink beverages, has become the largest Hemp CBD beverage by market share in the U.S. – based on first-year sales, national expansion, distribution ...

European Commission approves Opdivo for advanced renal cell carcinoma

The European Commission has approved Bristol-Myers Squibb's Opdivo in combination with low-dose Yervoy for first-line treatment of patients with intermediate and poor risk advanced renal cell carcinoma (RCC).

Align Clinical CRO Publishes New Operational Data Exchange Standard for Life Sciences Industry Input

Industry group’s first technology standard to make it easier for sponsors and CROs to share information during clinical trials NEW YORK–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#CROslt;/agt;–Align Clinical CRO, a life sciences industry standards group that includes eight leading contract research organizatio...

Stem Cell Transplant May Help Some With Aggressive MS

TUESDAY, Jan. 15, 2019 -- A stem cell transplant may help some people with multiple sclerosis (MS) when standard drugs fail, a new clinical trial finds. The study focused on 110 patients with aggressive cases of MS: Their symptoms had flared up at...

Presbia meets audit milestone under revised ISO standard

Ireland-based Presbia has completed its ISO 13485:2016 audit with no major findings, allowing it to proceed with efforts to b -More- 

Cigna Employees Kick Off $25 Million Healthier Kids For Our Future Initiative By Combatting Childhood Hunger Globally

Global health service company Cigna Corporation (NYSE:CI) today kicks off Healthier Kids for Our Future, a $25 million five-year global initiative to improve the health and well-being of children. Cigna's 74,000 global employees will work together to put children on a healthier path, starting with reducing childhood hunger and improving nutrition in local ...

Keytruda cuts risk of death by 31% in esophageal cancer trial

MSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma or adenocarcinoma who progressed after standard therapy. The results, from the phase 3 KEYNOTE-181 study, pave the way for yet anothe...

Early Extubation to Noninvasive Ventilation Does Not Reduce Time to Liberation From All Mechanical Ventilation

In this multicenter, randomized, open-label trial of patients who failed a spontaneous breathing trial, those who were extubated to noninvasive ventilation did not have a shorter time to liberation from any form of mechanical ventilation compared to those who were randomized to protocolized standard weaning.

Recent Developments in Breast Cancer

(MedPage Today) -- New HER2+ standard, CDK4/6 survival bump, skipping chemotherapy

Constantia Flexibles Introduces Flexible Blister Packaging

Portable packaging provides barrier integrity similar to standard blister solutions

Effect of standard light illumination on electrolyte’s stability of lithium-ion batteries based on ethylene and di-methyl carbonates

Arbor Biosciences and the IWGSC Partner on Wheat Exome

Arbor Biosciences, a worldwide leader in next generation sequencing (NGS) target enrichment and synthetic biology, announces their partnership with the International Wheat Genome Sequencing Consortium (IWGSC), an international organization dedicated to developing a gold-standard reference genome for bread wheat cv. Chinese Spring. This strategic partnership will provide IWGSC members with a standa...

The Importance of System Calibration and Verification for a TOC Instrument

Measuring total oxidizable carbon (TOC) in water has become a standard quality test for many industries...

Monday 14th January 2019

[Comment] New developments on interferon-γ release assays for tuberculosis diagnosis

To diagnose or exclude tuberculosis can be challenging because of the varied clinical signs and the limitations of diagnostic tests. Tuberculosis diagnosis has evolved from autopsies and histology to radiography and microbiological tests, with culture as the ultimate gold standard. Interferon-γ release assays (IGRAs) measure T-cell responses to Mycobacterium tuberculosis-specific antigens. Althou...

Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI) Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second-line treat...

$BMY EC Approves Opdivo Plus Low-Dose Yervoy for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

$BMY EC Approves Opdivo Plus Low-Dose Yervoy for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Quick Search


News Quicklinks